and/or oral deferasirox. Antiviral therapy with sofosbuvir (SOF) and ledipasvir (LDV) was started for 12 weeks. All patients achieved sustained virologic response (SVR). Treatment was safe and well tolerated, kidney function remained stable, and the only adverse events were mild asthenia and headache. Iron chelation concomitant medications remained unmodified during treatment, as well as the frequency of blood transfusions. Ferritin levels decreased during therapy in three patients, but in two of them returned to baseline levels at FU3. A reduction of liver stiffness, assessed by transient elastography, occurred from baseline to FU3 in all subjects. All SF36 scales related to mental health and to physical health significantly improved at FU6 compared to baseline ( Table 2 ).
The present case series suggests that 12-week-combination therapy of SOF/LDV is effective and safe in transfusiondependent β-thalassemia patients with advanced liver fibrosis. Remarkably, no impact of SOF on kidney function was observed as e-GFR values remained stable during therapy and FU.
To our knowledge, no data exist on the interactions between DAAs and iron chelation drugs. We employed SOF and LDV in these patients because this drug combination is associated with limited interactions [6] . Remarkably, in none of the cases, it was necessary to modify iron chelation therapy, and no changes in transfusion requests occurred. Moreover, serum ferritin values, an indirect marker of iron chelation efficacy, showed an improvement during antiviral therapy in all patients but one who reported poor compliance to iron chelation therapy during DAA treatment.
A marked improvement of liver stiffness, which correlates with fibrosis stage assessed by liver biopsy [7] , was observed in all patients. This result may be partly due to a reduction and control of liver inflammation [8] ; however, an initial regression of liver fibrosis might also have occurred, which is an important outcome in thalassemic patients, given their rapid fibrosis progression.
Both thalassemia major and CHC affect HRQOL [2, 3, 9] , but the contribution of CHC to the impaired HRQOL of 85  100  100  25  85  87  100  68   2  T0  50  50  41  5  30  37  33  40   FU6  85  100  84  56  85  87  100  76  3  T0  90  100  84  10  50  75  100  52   FU6  95  100  100  37  85  100  100  76   4  T 0  7 5  8 0  7 2  2 0  5 0  5 5  6 0  5 4  FU6  91  94  90  35  83  90  100  70 thalassemic patients has never been assessed. In our case series, a striking improvement of physical and mental dimensions of health, assessed by SF-36 questionnaire, occurred in all patients after HCV cure. This finding suggests that HCV infection plays a prominent, though probably underestimated, role on the impairment of HRQOL of thalassemic patients, and that antiviral treatment has the capacity to affect also this important aspect of patient's health.
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